Oncolytic

“This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,” said Dr. Stephen Russell, a Mayo Clinic hematologist, and first author of the paper and co-developer of the therapy in a statement.

Using re-engineered viruses to fight cancer, also known as oncolytic virotherapy, is nothing new, dating back to the 1950s, according to the Mayo Clinic.